BI 10773

Known as: BI-10773, BI10773 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2017
01220102017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Circulation. 2017;135:720–723. DOI: 10.1161/CIRCULATIONAHA.116.024627 720 L. Maria Belalcazar, MD Christie M. Ballantyne, MD Look… (More)
Is this relevant?
Review
2016
Review
2016
September 6, 2016 773 HE PLSE In late June 2016, the Endocrinologic and Metabolic Drugs Advisory Committee of the US Food and… (More)
Is this relevant?
Review
2015
Review
2015
Empagliflozin (formerly known as BI 10773) is a potent, competitive, and selective inhibitor of the sodium glucose transporter… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Empagliflozin is an orally available, selective inhibitor of sodium glucose cotransporter 2. In this study, single oral doses of… (More)
Is this relevant?
Review
2013
Review
2013
Inhibiting sodium-glucose co-transporters (SGLT1/SGLT2), which have a key role in the absorption of glucose in the kidney and/or… (More)
Is this relevant?
Review
2010
Review
2010
BI-10773, being developed by Boehringer Ingelheim Corp, is a sodium-glucose cotransporter (SGLT)2 inhibitor for the oral… (More)
Is this relevant?